Johnson Investment Counsel Inc. Boosts Stock Holdings in Charles River Laboratories International, Inc. $CRL

Johnson Investment Counsel Inc. lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 16.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,876 shares of the medical research company’s stock after purchasing an additional 3,306 shares during the period. Johnson Investment Counsel Inc.’s holdings in Charles River Laboratories International were worth $3,736,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its holdings in Charles River Laboratories International by 50.0% in the third quarter. ProShare Advisors LLC now owns 13,153 shares of the medical research company’s stock valued at $2,058,000 after buying an additional 4,386 shares in the last quarter. Azzad Asset Management Inc. ADV acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at about $831,000. Smartleaf Asset Management LLC increased its stake in shares of Charles River Laboratories International by 82.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 650 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 294 shares in the last quarter. Canada Post Corp Registered Pension Plan raised its holdings in Charles River Laboratories International by 1,363.2% in the 3rd quarter. Canada Post Corp Registered Pension Plan now owns 9,072 shares of the medical research company’s stock worth $1,333,000 after purchasing an additional 8,452 shares during the period. Finally, Bessemer Group Inc. boosted its position in Charles River Laboratories International by 10.0% during the third quarter. Bessemer Group Inc. now owns 5,036 shares of the medical research company’s stock worth $788,000 after purchasing an additional 458 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on CRL shares. Citigroup boosted their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Robert W. Baird set a $224.00 price target on shares of Charles River Laboratories International in a research note on Friday, January 9th. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a report on Monday, December 15th. Wall Street Zen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average target price of $209.46.

Charles River Laboratories International Trading Down 2.4%

Shares of CRL opened at $181.16 on Wednesday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88. The stock has a market cap of $8.92 billion, a PE ratio of -116.13, a price-to-earnings-growth ratio of 5.57 and a beta of 1.63. The firm’s fifty day moving average is $204.63 and its two-hundred day moving average is $180.05. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.